Filing Flows › Comparisons › PFE vs BMY
Pfizer vs Bristol Myers Squibb: PFE and BMY compared
Pfizer is the larger company: $16.6B of revenue in its latest quarter (Q3 2026) against $13.1B for Bristol Myers Squibb (Q3 2026). Bristol Myers Squibb is growing faster (+7% against -0.4% a year earlier). Pfizer is more profitable, with an operating margin of 20.4% against 19.4%.
Where the money goes: PFE and BMY
Pfizer (PFE) · Q3 2026
Pfizer, Q3 2026: revenue $16.6B (-0.4% year over year), operating margin 20.4%, net earnings $3.3B, operating cash flow $5.4B. The chart follows the revenue to costs, profit and cash.
Bristol Myers Squibb (BMY) · Q3 2026
Bristol Myers Squibb, Q3 2026: revenue $13.1B (+7% year over year), operating margin 19.4%, net earnings $2.2B, operating cash flow $4.2B. The chart follows the revenue to costs, profit and cash.
| Pfizer (PFE) | Bristol Myers Squibb (BMY) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $16.6B | $13.1B |
| Revenue growth, Y/Y | -0.4% | +7% |
| Operating margin | 20.4% | 19.4% |
| Net earnings | $3.3B | $2.2B |
| Net margin | 19.6% | 16.5% |
| Operating cash flow | $5.4B | $4.2B |
| Free cash flow | $4.8B | $3.8B |
| Market value | $169.0B | $127.6B |
| P/E | 42.0× | 13.7× |
| Analysts’ mean target | $30.11 | $65.25 |
Where the revenue comes from
Bristol Myers Squibb
- Net product sales: $12.6B (97%)
- Camzyos: $420M (3%)
Questions
Which is bigger, Pfizer or Bristol Myers Squibb?
Pfizer is the larger company: $16.6B of revenue in its latest quarter (Q3 2026) against $13.1B for Bristol Myers Squibb (Q3 2026).
Is Pfizer or Bristol Myers Squibb growing faster?
Bristol Myers Squibb is growing faster (+7% against -0.4% a year earlier).
Which is more profitable, Pfizer or Bristol Myers Squibb?
Pfizer is more profitable, with an operating margin of 20.4% against 19.4%.
More: Pfizer earnings · how Pfizer makes money · Bristol Myers Squibb earnings · how Bristol Myers Squibb makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 10-Q filed Oct 29, 2026). Fiscal quarters can end on different dates. Not investment advice.